These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12171566)

  • 1. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.
    Boyer SJ
    Curr Top Med Chem; 2002 Sep; 2(9):973-1000. PubMed ID: 12171566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents.
    Hartman GD; Fraley ME; Bilodeau MT
    Expert Opin Investig Drugs; 2002 Jun; 11(6):737-45. PubMed ID: 12036418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.
    Underiner TL; Ruggeri B; Gingrich DE
    Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
    Lee WS; Pyun BJ; Kim SW; Shim SR; Nam JR; Yoo JY; Jin Y; Jin J; Kwon YG; Yun CO; Nam DH; Oh K; Lee DS; Lee SH; Yoo JS
    MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling.
    Thieltges KM; Avramovic D; Piscitelli CL; Markovic-Mueller S; Binz HK; Ballmer-Hofer K
    Angiogenesis; 2018 Aug; 21(3):533-543. PubMed ID: 29502220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
    Shi L; Zhou J; Wu J; Shen Y; Li X
    Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitors.
    Manley PJ; Balitza AE; Bilodeau MT; Coll KE; Hartman GD; McFall RC; Rickert KW; Rodman LD; Thomas KA
    Bioorg Med Chem Lett; 2003 May; 13(10):1673-7. PubMed ID: 12729639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
    Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL
    Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective.
    Paz K; Zhu Z
    Front Biosci; 2005 May; 10():1415-39. PubMed ID: 15769635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors.
    Kojima-Yuasa A; Hua JJ; Kennedy DO; Matsui-Yuasa I
    Life Sci; 2003 Jul; 73(10):1299-313. PubMed ID: 12850245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
    Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase.
    Zhao G; Peery RB; Yingling JM
    Anal Biochem; 2007 Jan; 360(2):196-206. PubMed ID: 17141171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells.
    Miura S; Matsuo Y; Saku K
    Hypertension; 2003 May; 41(5):1118-23. PubMed ID: 12654712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
    Salerno S; García-Argáez AN; Barresi E; Taliani S; Simorini F; La Motta C; Amendola G; Tomassi S; Cosconati S; Novellino E; Da Settimo F; Marini AM; Via LD
    Eur J Med Chem; 2018 Apr; 150():446-456. PubMed ID: 29547832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.